Literature DB >> 984784

Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

F Leitner, M Misiek, T A Pursiano, R E Buck, D R Chisholm, R G DeRegis, Y H Tsai, K E Price.   

Abstract

Biological and physicochemical properties of BL-S786 were compared with those of cephalothin, cephaloridine, and cefazolin. With few exceptions, BL-S786 was more active than the reference compounds against major gram-negative pathogenic species and its antibacterial spectrum was broader than that of cephalosporins currently available for clinical use. Although BL-S786 was generally less active than the control cephalosporins against gram-positive pathogens, it inhibited their growth at concentrations that should readily be achieved in humans after standard parenteral dosage. Streptococcus faecalis, a species relatively unsusceptible to cephalosporins in general, was an exception. BL-S786 was an effective bactericidal agent for strains of various gram-negative organisms. After intramuscular administration to mice, BL-S786 achieved high concentrations in blood, and its biological half-life was longer than that of the other three cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984784      PMCID: PMC429765          DOI: 10.1128/AAC.10.3.426

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  [The binding of penicillins on the proteins of the blood and tissues].

Authors:  W SCHOLTAN; J SCHMID
Journal:  Arzneimittelforschung       Date:  1962-08

2.  BL-S 640, a cephalosporin with a broad spectrum of antibacterial activity: properties in vitro.

Authors:  F Leitner; R E Buck; M Misiek; T A Pursiano; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

3.  BL-S640, a cephalosporin with a broad spectrum of antibacterial activity: bioavailability and therapeutic properties in rodents.

Authors:  F Leitner; D R Chisholm; Y H Tsai; G E Wright; R G Deregis; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

Review 4.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

  4 in total
  17 in total

1.  Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Authors:  R D Smyth; M Pfeffer; A Glick; D R Van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  Pharmacokinetics of ceforanide.

Authors:  S Ripa; F La Rosa; A Ghezzi; M Prenna; M Pfeffer
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

3.  Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.

Authors:  J R Hess; S J Berman; W H Boughton; J G Sugihara; J E Musgrave; E G Wong; A M Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Authors:  P Actor; J V Uri; I Zajac; J R Guarini; L Phillips; D H Pitkin; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

Review 5.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

6.  Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia.

Authors:  R J Wallace; R R Martin; S B Greenberg
Journal:  Infection       Date:  1979       Impact factor: 3.553

7.  Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats.

Authors:  F H Lee; R D Smyth; D R Van Harken
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

8.  Use of a heavy inoculum in the in vitro evaluation of the anti-staphylococcal activity of 19 cephalosporins.

Authors:  M Laverdiere; D Welter; L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

9.  In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.

Authors:  S Shadomy; G Wagner; M Carver
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

10.  BL-S786 (ceforanide), a new parenteral cephalosporin: in vitro studies.

Authors:  S S Weaver; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.